About 200 reports

WEAKNESSES THE ORAL DOSAGE FORM PROVIDES EASE OF ADMINISTRATION.

  • Digestive System Disorder
  • Allergan plc
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • Ironwood Pharmaceuticals, Inc.
  • ASTRAZENECA

It is an oral administration drug.

  • Digestive System Disorder
  • Forecast
  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Furthermore, its oral administration will provide a more convenient method for patients with NASH.

  • Digestive System Disorder
  • Market Size
  • Allergan plc
  • Genfit SA
  • Gilead Sciences, Inc.

Although some authors have argued that oral administration may Chapter IV ## Page DIGESTIVE REMEDIES PRODUCTION AND DEMAND ##.

  • Digestive System Disorder
  • China
  • Demand
  • Trade
  • AstraZeneca PLC
  • EMRICASAN SWOT ANALYSIS
  • PRODUCT PROFILE - EMRICASAN

IN A PHASE I/ IIA TRIAL, ORAL ADMINISTRATION OF IMM-##E WAS PROVEN TO BE SAFE IN PATIENTS WITH TYPE ## DIABETES, HYPERLIPIDEMIA, AND NASH.

  • Digestive System Disorder
  • United States
  • Conatus Pharmaceuticals Inc.
  • Galectin Therapeutics Inc.
  • Gilead Sciences, Inc.
  • 3.11 Amitiza (lubiprostone)

Amitiza is available for oral administration.

  • Digestive System Disorder
  • Market Size
  • AbbVie Inc.
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • RQ-00201894 - DRUG PROFILE

It is formulated as film-coated tablets for oral route of administration.

  • Digestive System Disorder
  • Japan
  • World
  • Product Initiative
  • RaQualia Pharma Inc.
  • ESOMEPRAZOLE - DRUG PROFILE
  • IYHCR-17 - DRUG PROFILE

It is formulated as enteric-coated tablets for oral administration.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative

The drug candidate is administered by oral route.

  • Biguanide
  • Biopharmaceutical
  • Diabetes
  • Digestive System Disorder
  • Therapy
  • RQ-00201894 - DRUG PROFILE

It is formulated as film-coated tablets for oral route of administration.

  • Digestive System Disorder
  • Japan
  • World
  • Product Initiative
  • RaQualia Pharma Inc.
  • PMKS-005 - DRUG PROFILE
  • Phase I - Trial Details

It is formulated as film coated tablets for oral route of administration.

  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • R&D Progress
  • ELAFIBRANOR - DRUG PROFILE

IT IS FORMULATED AS FILM-COATED TABLETS ORAL ROUTE OF ADMINISTRATION.

  • Autoimmune Disease
  • Digestive System Disorder
  • Therapy
  • United States
  • Product Initiative
  • ESOMEPRAZOLE - DRUG PROFILE
  • National Institutes of Health.

It is formulated as enteric-coated tablets for oral administration.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative

It is formulated as film coated tablets for oral route of administration.

  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • Evoke Pharma, Inc.
  • DA-6886 - DRUG PROFILE
  • SK-1202 - DRUG PROFILE

It is formulated as capsules for oral route of administration.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative

The drug candidate is administered by oral route.

  • Biguanide
  • Digestive System Disorder
  • Therapy
  • United States
  • GlaxoSmithKline plc
  • PMKS-005 - DRUG PROFILE
  • Peptic Ulcers - Drug Profiles

It is administered through oral route.

  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • PMKS-005 - DRUG PROFILE
  • Gastric Ulcers - Drug Profiles

It is administered through oral route.

  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Litigation And Patent
  • AstraZeneca PLC
  • RG-7625 - Drug Profile

It is administered orally.

  • Digestive System Disorder
  • United States
  • World
  • Product Initiative
  • Virobay Inc.

Claims include multiple routes of administration including intravenous, subcutaneous and oral.

  • Digestive System Disorder
  • United States
  • World
  • Product Initiative
  • Galectin Therapeutics Inc.

The secondary outcome measure was to determine general tolerance assessment after administration of one dose of SYL## (period ##) and after ## days administration (period ##).

  • Chronic Pain
  • Digestive System Disorder
  • Therapy
  • United States
  • Flex Pharma, Inc.

In the CCL## fibrosis model, the oral administration of IMM-##E significantly decreased the levels of liver enzymes and bilirubin, thereby alleviating the liver injury.

  • Digestive System Disorder
  • United States
  • Enterome Bioscience SA
  • MicroBiome Therapeutics LLC
  • Seres Therapeutics, Inc.

In addition, in line with expectations, the trial showed minimal systemic absorption following oral administration, which is desirable for targeted topical activity within the gut.

  • Digestive System Disorder
  • Healthcare
  • United States
  • World
  • Product Initiative
  • SK-1202 - DRUG PROFILE
  • DA-6886 - DRUG PROFILE

It is formulated as capsules for oral route of administration.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative
  • ORNITHINE PHENYLACETATE - DRUG PROFILE

Food and Drug Administration.

  • Digestive System Disorder
  • Neurological Disorder
  • Therapy
  • United States
  • Ocera Therapeutics, Inc.
  • ELAFIBRANOR - DRUG PROFILE

Forty eight monkeys received a daily oral administration of IVA## at doses of ##, ## or ## mg/ kg/ day or placebo for ## weeks.

  • Digestive System Disorder
  • Therapy
  • United States
  • Product Initiative
  • Genfit SA
  • Clinical Trial profile. 384 Trial Title
  • Target

Twice Daily Oral Administration of ## mg Naproxen and Once Daily Oral Administration of Esomeprazole (## mg) in Healthy Volunteers A Randomized, Ope-label, Four Way Cross-over Study to Evalaute the Effect of Twice Daily Oral Administration of Th

  • Clinical Trial
  • Digestive System Disorder
  • Therapy
  • World
  • AstraZeneca PLC

It is administered orally as a tablet.

  • Digestive System Disorder
  • Therapy
  • World
  • Product Initiative
  • Gilead Sciences, Inc.
  • HEPATIC ENCEPHALOPATHY - PIPELINE BY ALFASIGMA SPA, H2 2018
  • HEPATIC ENCEPHALOPATHY - PIPELINE BY COSMO PHARMACEUTICALS NV, H2 2018

Food and Drug Administration.

  • Digestive System Disorder
  • Neurological Disorder
  • Therapy
  • United States
  • Ocera Therapeutics, Inc.

It is formulated as concentrate for solution, as injection for intravenous administration and capsule for oral administration.

  • Digestive System Disorder
  • In Vitro Diagnostic Reagent
  • Pharmaceutical
  • Therapy
  • Transplantation